Please login to the form below
CAR-T therapy
This page shows the latest CAR-T therapy news and features for those working in and with pharma, biotech and healthcare.
AZ makes gene therapy move with 4DMT alliance
AZ makes gene therapy move with 4DMT alliance. The new partnership will focus on creating an AAV for lung disease. ... therapy medicinal products (ATMPs) such as gene and cell therapies, other than indirectly – for example its collaboration pairing a
Latest news
-
The year of the blockbuster
The therapy was filed in Japan in March and an EU filing (February) is also pending. ... These include Juno Therapeutics’CAR T-cell therapy, lisocabtagene maraleucel, for diffuse large B-cell lymphoma, and Alexion’s next-generation Soliris treatment,
-
New trial results suggest CAR-T effects are durable in lymphoma
said backed up their claim the CAR-T is potentially ‘best-in-class’. ... There are plenty of other factors to consider when determining which of the three tops the pile in CAR-T therapy for B-cell lymphomas.
-
More impressive data from Bluebird’s gene therapy in thalassemia and sickle cell disease
These two major clinical trial programmes are not Bluebird’s only promising candidates – it also has bb2121, its anti-BCMA CAR T Cell Therapy for Relapsed/Refractory Multiple Myeloma in development ... with Celgene, plus Lenti-D, a gene therapy for
-
Daily Brief: Tagrisso's first line approval, EULAR and EHA, and why Stephen Hawking was wrong on NHS
Some of the most eyecatching data includes updates from Novartis on its CAR-T therapy Kymriah in (DLBCL) and r/r B-cell acute lymphoblastic leukemia (B-ALL) and bluebird’s ... LentiGlobin cell therapy in β-Thalassemia and severe Sickle Cell Disease.
-
Axovant bets on gene therapy with $842.5m Oxford BioMedica deal
Wright was involved in the development of Spark’s Luxturna, the first gene therapy to be approved in the US. ... It’s chief executive – John Dawson – said the deal was a “significant agreement”which reinforces the potential of its lentivirus
More from news
Approximately 4 fully matching, plus 41 partially matching documents found.
Latest Intelligence
-
No incentive for a cure
These include Kymriah, the pioneering CAR-T cell therapy from Novartis, which demonstrated a remarkable 83% remission rate in children and young adults with B-cell precursor acute lymphoblastic leukaemia. ... One of the biggest questions with a curative
-
Can value-based healthcare take off and reach for the skies?
CAR-T cell therapy for children with B-cell ALL. ... costs. It was then backed with a ‘no response-no payment’contract. It has also struck novel reimbursement packages with its heart failure therapy Entresto and its psoriasis treatment Cosentyx.
-
The rise of real-world evidence
Novartis secured such an outcome-based model for its CAR-T therapy Kymriah. ... Spark Therapeutics has a similar arrangement for its gene therapy. These agreements make real-world efficacy a requirement for full payment for a drug.
-
Deal Watch January 2018
Having terminated the development of its lead CAR-T therapy, JCAR015, early last year after several patient deaths in a phase II clinical trial in relapsed/refractory B-cell acute lymphoblastic ... Juno Therapeutics/ Celgene. CAR-T and TCR therapeutics
-
The gold standard of scientific evidence
Additionally, RWE is being used to inform. creative drug pricing. When seeking coverage for Kymriah, a new CAR-T therapy, Novartis has an agreement with the Centers for Medicaid and Medicare
More from intelligence
Approximately 0 fully matching, plus 15 partially matching documents found.
Latest appointments
-
Celgene boosts CAR-T stake again with Bluebird Bio deal
Mere weeks after completing its acquisition of CAR-T specialist Juno, Celgene has added to its cell therapy pipeline with another clinical-stage CAR-T candidate from Bluebird Bio. ... It could also receive additional, undisclosed milestones if the CAR-T
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Training the next generation of biotech leaders
In this year alone, the FDA has taken the groundbreaking step of approving two CAR-T therapies. ... In August, Novartis’ revolutionary CAR-T therapy, Kymriah, was approved. This was quickly followed by the approval of Kite’ s Yescarta in October.
-
Innovation in pharma: the highs and lows of the current healthcare economy
Gene therapies often require a ‘ one-time only’ treatment offering life-changing potential to patients with conditions where currently there may be no available therapy at all, for instance, in rare ... Also in cancers: chimeric antigen receptor T
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
Featured jobs
- Principal Medical Writer / Editorial Director – Medical Communic...
-
£60, 000 - £80, 000
- Senior Project Manager - Medical Writing
-
Great salary and bebefits
-
Client Services Director - Med Comms
-
Great salary and bebefits
- Home based, Editorial Team Leader, Medical Communications
-
Excellent package
-
Account Manager
-
£40, 000 - £45, 000 benefits
- Home based, Chief Medical Writer, Medical Communications
-
Excellent package
- Home based, Senior Medical Writer, Medical Communications
-
Excellent package
- Home based, Principal Medical Writer, Medical Communications
-
Excellent package
- Multi-Channel Account Managers - Road / Homebased – Full or Part...
-
Competitive salary
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
- Business Unit Head, Medical Communications, London
-
Excellent package
-
Senior Account Manager
-
Competitive salary commensurate with experience
- Account Director, Consumer Healthcare PR, Global PR agency
-
£50, 000 – £58, 000
- Strategic Planner, Healthcare Advertising
-
£47, 000 – £53, 000
- Account Director, Medical Communications
-
C£50 – 65, 000 benefits and bonus
- Head of Market Access - International - Based Cambridge
-
Excellent Basic, Bonus and Flex Benefits
Subscribe to our email news alerts
- Communiqué Awards 2018: Photo Gallery - Communiqué Awards 2016
- NHS England says yes to Roche's Hemlibra
- Moving annual total (MAT)
- Vertex to Theresa May: Orkambi verdict ‘threatens bio investment’
- GSK sells eczema and psoriasis drug to Dermavant for £250m
- Communiqué Awards 2018: Winners in pictures - Communiqué Awards 2016
- May’s Brexit plan cautiously welcomed by biopharma sector
- Daily Brief: Novartis exits anti-infectives drive, Hancock takes over from Hunt and Trump attacks 'soft Brexit' plan
- GSK sells eczema and psoriasis drug to Dermavant for £250m
- Fishawack acquires brand communications agency Healthcircle
- Roche keeps Venclexta train rolling with new leukaemia filing
- Pfizer builds gap between pharma and consumer health units
PMHub
Ashfield
Transforming healthcare outsourcing. From small beginnings in 1997, Ashfield has grown rapidly into an international healthcare services organisation. By anticipating...
Latest intelligence
- Digital trends in B2B sales - how far behind is Pharma?
- The modern approach to B2B sales is data-driven, and enabled by digital tools....
- The rise of vertical integration in the US payer landscape
- Is it a solution to addressing the challenges of the value-based marketplace?...
- Creativity has lost its worth
- Creativity has lost its worth, and sadly it is undermining effectiveness...
Quick links
Infographics
